CD8A and neoplasm: A novel glutamine antagonist, JHU083, reduces tumor growth by inhibiting glutamine uptake for anabolism in cancer cells and enhancing the cell killing ability of CD8+ T cells in the microenvironment, providing a new therapeutic strategy based on glutamine metabolism (25).